News | October 24, 2013

Transcatheter Technologies Successfully Implants Human With Repositionable Trinity Transapical Aortic Valve

Clinical data to be presented at TCT 2013

heart valve repair clinical trial study transcatheter aortic valve trinity
October 24, 2013 — Transcatheter Technologies GmbH, a medical device company, announced the successful first-in-human implantation of its transapical Trinity aortic valve.
 
“A major limitation of existing transcatheter aortic heart valves is that they cannot be repositioned once implanted. Trinity, however, is designed to solve this difficult problem,” said Wolfgang Goetz, M.D., Ph.D., CEO, Transcatheter Technologies. “With Trinity, once our valve is initially placed, a cardiologist can fully evaluate the valve’s function to determine whether it needs to be repositioned, retrieved or kept in the same position.  Equally important, Trinity provides for a controlled positioning by allowing a cardiologist to slowly open the valve stent, thus improving the likelihood of a first-attempt correct placement.”
 
“The Trinity aortic valve can be positioned precisely. Yet, it also allows for safe repositioning of the valve prosthesis — or even full retrieval — if necessary. Its unique sealing cuff provides excellent results without paravalvular leakage. Moreover, the risk for atrio-ventricular block is dramatically reduced due to the supraannular positioning of Trinity,” said Dr. Christian Hengstenberg, cardiologist, German Heart Centre, Munich, Germany.
 
The results of the first-in-human clinical trial using Trinity will be presented at the annual Transcatheter Cardiovascular Therapeutics (TCT) Meeting on Oct. 28, 2013 in San Francisco.
 
For more information: www.transcathetertechnologies.com
 

Related Content

Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
PQ Bypass Reports Positive Results for Detour System in Patients With Long Femoropopliteal Blockages
News | Peripheral Artery Disease (PAD)| September 13, 2017
A subset analysis of the DETOUR I clinical trial showed promising safety and effectiveness results of PQ Bypass’ Detour...
News | Cardiac Diagnostics| September 12, 2017
Contracting shingles, a reactivation of the chickenpox virus, increases a person’s risk of stroke and heart attack,...
Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study in Denmark

Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study. Photo credit: Lisbeth Hasager Justesen, Viborg Hospital.

News | Cardiac Diagnostics| September 12, 2017
September 12, 2017 — A new screening program for vascular disease saves one life for every 169 men assessed, accordin
News | Pharmaceuticals| September 12, 2017
September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in pati
Overlay Init